Roche

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

All mentioned trademarks are legally protected.

Roche

Q1 2023 sales

Basel, 26 April 2023

Group

Thomas Schinecker
Chief Executive Officer

Q1 2023 performance

Outlook

Q1 2023: Strong underlying sales excluding COVID-19 decline

Roche

Group sales -3% driven by expected decline in COVID-19 testing

- Strong Pharma performance (+9%) driven by ongoing portfolio rejuvenation
- Good Diagnostics base business growth (+4%)
- COVID-19 sales decline in line with FY 2023 expectations

Growth supported by key products and strong launches

- Pharma key products Vabysmo, Ocrevus, Hemlibra, Evrysdi, Tecentriq, Perjeta, Phesgo and Polivy continuing to grow strongly
- Key Pharma approvals: Polivy in 1L DLBCL in the US, Hemlibra in moderate hem A in the EU, Columvi (glofitamab) in 3L+ DLBCL in Canada
- Diagnostics: launches of new tests in oncology, navify Algorithm Suite and navify Marketplace

Update on pipeline newsflow in 2023

- Positive Phase III results for Tecentriq + Avastin in adjuvant HCC and crovalimab in PNH achieved
- Pharma: 14 upcoming late-stage read-outs incl. 2 NMEs (tiragolumab, SRP-9001) and important line extensions for Ocrevus, Tecentriq, Venclexta, TNKase, Alecensa and Lunsumio
- Diagnostics: CCM Vertical, LightCycler Pro, Anti-HEV IgG/IgM, HBeAg Quant, and IL-6 Neonatal sepsis

Growth rates at CER (Constant exchange Rates); DLBCL= diffuse large B-Cell lymphoma; NME=new molecular entity; HCC=hepatocellular carcinoma; PNH=paroxysmal nocturnal hemoglobinuria

Q1 2023: Group sales decline driven by COVID-19 sales erosion

	2023 CHFbn	2022 CHFbn	Change in % CHF	Change in % CER	Excl. C19[1]
Pharmaceuticals Division	**11.7**	11.2	**5**	**9**	**9**
Diagnostics Division	**3.6**	5.3	**-31**	**-28**	**4**
Roche Group	**15.3**	16.4	**-7**	**-3**	**8**

CER=Constant Exchange Rates; totals may include differences due to rounding; [1] Pharmaceuticals Division sales excluding Ronapreve, Diagnostics Division base business

Q1 2023: Portfolio diversification ongoing



Diversification of Roche portfolio



Values in reported CHFm, variances in CERm; [1] AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion

Q1 2023: Strong underlying growth in Pharma and Diagnostics

Pharma
Quarterly sales evolution 2022-2023



Diagnostics
Quarterly sales evolution 2022-2023



Growth rates at CER (Constant Exchange Rates)

Portfolio rejuvenation progressing; new launches with >50% of sales

*Columvi (glofitamab): first NME launch in 2023**



*First launch in Canada, PDUFA date in the US is July 1st; ** SRP-9001: Accelerated US-filing by partner company Sarepta; crovalimab: First filing in China; ***Venclexta sales booked by AbbVie and therefore not included

2023 performance

Outlook

2023: Upcoming newsflow

Pharma

Tiragolumab + Tecentriq in 1L PDL1+ NSCLC	**Glofitamab + GemOx** in 2L+ DLBCL
Tiragolumab + Tecentriq + chemo in 1L Esophageal	**Lunsumio + Polivy** in 2L+ DLBCL*
Tecentriq + Avastin in adjuvant HCC ✓	**Crovalimab** in PNH ✓
Tecentriq in adjuvant SCCHN	**Delandistrogene moxeparvovec (SRP-9001)** in DMD
Tecentriq + chemo in adjuvant TNBC ✗	**Ocrevus 6m SC** in RMS / PPMS
Tecentriq neoadjuvant/adjuvant TNBC	**TNKase** in Stroke
Phesgo OBI in HER2+ BC	**Susvimo** in DME ✓
Alecensa in adjuvant ALK+ NSCLC	**Susvimo** in DR ✓
Venclexta + azacitidine in 1L high risk MDS	**Xolair** in Food allergy
Venclexta + dexamethasone in R/R MM (t11;14)	

Diagnostics

CCM Vertical	Modular transportation system, integrated into existing cobas connection modules
LightCycler Pro	Flexible real-time PCR instrument with dual IVD and Research mode
Anti-HEV IgG and Anti-HEV IgM	Anti-HEV IgM: Immunoassay aiding in diagnosis of acute HEV infection in clinic. Anti-HEV IgG: Immunoassay aiding in detection of a recent or past HEV infection
HBeAg Quant	Immunoassay aiding in diagnosis, monitoring and predicting treatment response for patients with hepatitis B
IL-6 Neonatal sepsis (claim extension)	Immunoassay with dedicated claim aiding in diagnosis of sepsis in neonates

Neuroscience
Oncology/Hematology
Ophthalmology
Immunology

DME=diabetic macular edema; DLBCL=diffuse large B-cell lymphoma; NSCLC=non-small cell lung cancer; HCC=hepatocellular carcinoma; MM=multiple myeloma; PCR=polymerase chain reaction; SC=subcutaneous; DR=diabetic retinopathy; RMS=relapsing MS; PPMS=primary progressive MS; PNH=Paroxysmal nocturnal hemoglobinuria; TNBC=triple negative breast cancer; SCCHN=squamous cell carcinoma of head and neck; DMD=Duchenne muscular dystrophy; OBI=on-body injector; BC=breast cancer; MDS=Myelodysplastic syndrome; R/R=relapsed / refractory; IVD=in vitro diagnostics; HEV=Hepatitis E Virus; *Results are event-driven, read-outs expected 2023/24

Corporate Executive Committee

Since April 2023

Thomas Schinecker
CEO Group

Pharma Division

Teresa Graham
Pharma CEO*

Levi Garraway
Head of Pharma Dev / CMO*

Hans Clevers
Head of pRED

Aviv Regev
Head of gRED

James Sabry
Head of Partnering

Diagnostics Division

Matt Sause
Diagnostics CEO

Group Functions

Alan Hippe
CFO / CIO

Cris Wilbur
Chief People Officer

Claudia Boeckstiegel
General Counsel

Barbara Schaedler
Head of Group Comms

Silke Hoernstein
Head of Strategy & Sustainability

*Co-chair late stage pipeline committee (LSPC); pRED=Pharma Research & Early Development; gRED=Genentech Research & Early Development

2023 sales outlook

Sales drivers[1]

Pharma: Key products with strong growth and momentum from ongoing launches

Diagnostics: Base business with solid growth

COVID-19 sales for Diagnostics and Pharma expected to decline by roughly CHF 5bn

AHR[2] sales expected to erode by roughly CHF 1.6bn

Group sales growth[1]	Low single digit decline

[1] At Constant Exchange Rates (CER); [2] AHR=Avastin, Herceptin, Rituxan/MabThera

2023 outlook

Group sales growth[1]	Low single digit decline
Core EPS growth[1]	Broadly in line with sales decline
Dividend outlook	Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pharmaceuticals Division

Teresa Graham
CEO Roche Pharmaceuticals

Q1 2023: Pharmaceuticals Division sales

All regions delivering strong growth

	2023 CHFm	2022 CHFm	Change in % CHF	Change in % CER
Pharmaceuticals Division	**11,699**	**11,159**	**5**	**9**
United States	5,853	5,489	7	6
Europe	2,071	2,072	0	5
Japan	1,390	1,337	4	18
International	2,385	2,261	5	13

CER=Constant Exchange Rates

Q1 2023: Strong momentum for key growth drivers

Vabysmo leading growth contributor after only 5 quarters



Absolute values and growth rates at Constant Exchange Rates (CER)

Q1 2023: Oncology portfolio growing +4%



HER2 franchise

- Kadcyla (+5%) with growth ex-US in adj. BC; China NRDL listing granted
- Perjeta (+11%) driven by US & International
- Phesgo (+72%): 35% conversion in early launch countries*

Tecentriq

- Solid growth (+15%) driven by adjuvant NSCLC and 1L HCC

Hematology franchise

- Venclexta**: Expanding patient share in 1L AML & 1L CLL
- Gazyva (+24%): Growth driven by 1L FL and 1L CLL
- Polivy (+96%): Strong 1L DLBCL uptake ex-US; FDA approval in 1L DLBCL
- Lunsumio: Global 3L+ FL launch ongoing; NCCN guideline inclusion as category 2A granted

Alecensa

- Good growth (+9%) and 1L ALK+ NSCLC leadership in major markets
- Ph III (ALINA) in adjuvant ALK+ NSCLC expected in 2023

Q1 2023 Oncology sales: CHF 4.9bn, CER growth +4%; CER=Constant Exchange Rates; * Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (30 countries); ** Venclexta sales booked by AbbVie and therefore not included; BC=breast cancer; NRDL=national reimbursement drug list; HCC=hepatocellular carcinoma; NSCLC=non-small cell lung cancer; AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; ALK=anaplastic lymphoma kinase; Polivy in collaboration with Seagen

Polivy in 1L DLBCL: FDA approval granted

Comprehensive NHL development program ongoing

Uptake in 1L DLBCL accelerating

1L DLBCL approved in >70 countries



Polivy quarterly sales



- FDA ODAC voted 11-2 in favor of clinical benefit in 1L DLBCL
- US approval granted with label for 1L DLBCL with IPI score 2-5
- US: Included in NCCN guideline as category 1*
- UK: NICE reimbursement obtained**

NHL development program progressing

Indication	Regimen	Ph I	Ph II	Ph III
2L+ DLBCL *(SCT ineligible)*	Polivy + R-GemOx	POLARGO		
2L+ DLBCL *(SCT ineligible)*	Lunsumio + Polivy	SUNMO		
2L+ DLBCL *(SCT ineligible)*	Columvi + GemOx	STARGLO		
1L DLBCL	Columvi + Polivy + R-CHP			
1L DLBCL *(elderly unfit)*	Lunsumio + Polivy			
2L+ DLBCL *(SCT ineligible)*	Columvi + Polivy			
2L FL	Lunsumio + lenalidomide	CELESTIMO		

- Ph III Columvi + Polivy + R-CHP in 1L DLBCL to be initiated in 2023
- Ph III (SUNMO) Lunsumio + Polivy in 2L+ DLBCL to read out in 2023/24
- Ph III (STARGLO) Columvi + GemOx in 2L+ DLBCL to read out in H2 2023

CER=constant exchange rates; NHL=Non-Hodgkin's lymphoma; DLBCL=diffuse large B-cell lymphoma; ODAC=oncologic drugs advisory committee; IPI=International prognostic index; FL=follicular lymphoma; R-GemOx=rituxan + gemcitabine + oxaliplatin; R-CH(O)P=rituxan + cyclophosphamide + doxorubicin + (vincristine) + prednisone; *NCCN guidelines for B-Cell Lymphomas (V1.2023); **NICE: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]; Polivy in collaboration with Seagen

Phesgo: Conversion rate in early launch countries climbing to 35%

Roche

PHESGO®

Phesgo reduces administration time & costs



Phesgo with strong global launch



- 85% of patients preferred Phesgo for Subcutaneous administration over the intravenous formulation of Perjeta and Herceptin
- Phesgo conversion rate at 35% in early launch countries, including strong uptake in the US and Germany
- Pivotal Ph I results for Phesgo OBI (on body injector) to enable patient self-administration expected in H2

Source: O'Shaughnessy J, et al. ESMO 2020 (Abstract 165MO); H=Herceptin; P=Perjeta; IV=Intravenous; *Ranges driven by differences in loading and maintenance dose; **Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (30 countries); Phesgo in collaboration with Halozyme

Divarasib in CRC: Positive early combination data at AACR

Potential for best-in-class profile

Divarasib (KRAS G12Ci)

FDA BTD

in vitro proliferation assay



- Irreversible covalent inhibitor of KRAS G12C
- More potent and selective *in vitro* than sotorasib and adagrasib
- Granted FDA BTD for 2L NSCLC
- KRAS is the most frequently mutated oncogene, occurring in more than 25% of all cancers

Ph Ib results for divarasib + cetuximab in advanced or metastatic CRC

ORR results



- Promising Ph Ib results in CRC with unconfirmed / confirmed ORR = 66 % / 62% and manageable safety profile
- Strong responses in several other indications, including 2L+ NSCLC
  - Confirmatory pivotal Ph III trial in 2L+ NSCLC initiated in Q4 2022
- Ph II/III (BFAST) with divarasib cohort in NSCLC ongoing

Source: Purkey et al. AACR 2022 ; Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation, Desai et al., AACR annual meeting 2023; KRAS=kirsten rat sarcoma; G12C=glycine-to-cysteine substitution at codon 12; IC_{50}=inhibitory concentration; BTD=breaktrough therapy designation; CRC=colorectal cancer; NSCLC=non-small cell lung cancer; ORR=overall response rate; SLD=sum of lesion diameter; SD=stable disease; PR=partial response; Lumakras (sotorasib) is a registered trademark/product of Amgen; Krazati (adagrasib) is a registered trademark/product of Mirati Therapeutics

Tecentriq: Solid growth across all regions

First PD-(L)1 with pivotal SC results filed and PDUFA set for September 15th



Q1 update

- Ph III (IMbrave050) results in adjuvant HCC presented at AACR; RFS primary endpoint met but OS immature
- Ph III (IMpassion030) in adjuvant TNBC to be discontinued

Lung franchise (NSCLC, SCLC)

- EU: Strong adjuvant NSCLC launch
- US: Growth in SCLC and adjuvant NSCLC

GI franchise (HCC)

- US/EU/Japan: Further growth in 1L HCC

Outlook 2023

- Ph III (IMvoke010) results in adjuvant SCCHN expected in H2
- Ph III (SKYSCRAPER-01) Tecentriq + tiragolumab in 1L NSCLC to continue to final analysis, expected in Q3

CER=Constant Exchange Rates; SC=subcutaneous; NSCLC=non-small cell lung cancer; HCC=hepatocellular cancer; SCLC=small cell lung cancer; TNBC=triple-negative breast cancer; SCCHN=squamous cell carcinoma of head and neck; PDUFA=prescription drug user fee act; RFS=recurrence free survival; OS=overall survival

Hemophilia A: Hemlibra the global standard of care

37% US/EU-5 patient share reached



Q1 update

- ~20,000 patients treated globally
- Hemlibra continues to penetrate across all approved patient segments
- EU: Label extension to moderate patients (HAVEN 6) granted

Outlook 2023

- US/EU: Further patient share gains in non-inhibitors
- SPK-8011 (dirloctocogene samoparvovec) pivotal Ph III to be initiated

CER=Constant Exchange Rates

Crovalimab: Positive Ph III results in PNH

Expanding into additional diseases: Ph I in LN initiated

Roche

IR virtual event June 12th

Ph III (COMMODORE 3) results in PNH

ASH 2022



Crovalimab development program

Indication		Ph I	Ph II	Ph III	
PNH	*Paroxysmal nocturnal hemoglobinuria*	**COMPOSER**			✓
		COMMODORE 1 (switch)			✓
		COMMODORE 2 (naïve)			✓
		COMMODORE 3 (China)			✓
aHUS	*Atypical hemolytic uremic syndrome*	**COMMUTE-a** (adults)			
		COMMUTE-p (pediatric)			
SCD	*Sickle cell disease*	**CROSSWALK-c** (chronic)			
		CROSSWALK-a (acute)			
LN	*Lupus nephritis*				

EHA 2023

- Ph III China (COMMODORE 3) results show that mean LDH ≤1.5 × ULN was reached by week 3 and maintained through week 25
- Ph III (COMMODORE 2/1) results show successful disease control in naïve patients, and a favorable benefit-risk profile for patients switching from other C5 inhibitors; Safety was consistent with the known safety profile of C5 inhibitors; Results to be presented at EHA 2023
- Filed in China (BTD, Priority Review) with approval expected in 2023; Global filing planned for H1 2023

Liu et al. ASH 2022; PNH=Paroxysmal nocturnal hemoglobinuria; LN=lupus nephritis; LDH=lactate dehydrogenase; ULN=upper limit of normal;; BTD=breakthrough therapy designation

Immunology: Actemra COVID-19 sales declining and Esbriet LOE

Xolair autoinjector approval and Ph III food allergy readout expected in 2023



Q1 updates

- Ph III (REGENCY) Gazyva in LN fully recruited; read out expected in 2024
- Ph III (INShore) Gazyva in PNS initiated

Actemra (-12%)

- COVID-19 related sales declining
- Shift from IV to SC ongoing, SC share at ~60%

Esbriet (-69%)

- Generic competition in US and EU

Xolair (+5%)

- Market leader in asthma biologics and strong growth in CSU

Outlook 2023

- US approval of Xolair autoinjector expected
- Ph III (OUtMATCH) in food allergy read out expected
- Ph III (IMAGINATION) ASO factor B in IgAN to be initiated

CER=Constant Exchange Rates; LOE=loss of exclusivity; RA=rheumatoid arthritis; IV=intravenous; SC=subcutaneous; LN=lupus nephritis; CSU=chronic spontaneous urticaria; ASO=antisense oligonucleotide; IgAN=immunoglobulin A nephropathy; PNS=pediatric nephrotic syndrome

Multiple Sclerosis: Ocrevus reaching 22% patient share

Ph III results for 6M SC Ocrevus expected in 2023



Q1 update

- >300k patients treated globally
- #1 treatment in US and EU-5, both in total share and new to brand share
- Higher retention rate than other MS medicines
- Ph III (GAVOTTE/MUSETTE) high-dose Ocrevus recruitment completion imminent

Outlook 2023

- US/EU: Further market share gains and growth expected
- Ph III (OCARINA II) Ocrevus SC with Q6M dosing in RMS & PPMS data read out expected
- First Ph II (FENopta) data for fenebrutinib in RMS expected

CER=Constant Exchange Rates; MS=multiple sclerosis; SC=subcutaneous; Q6M=every 6 months; RMS=relapsing MS; PPMS=primary progressive MS

Spinal Muscular Atrophy: Evrysdi market leader in US and Japan

Increasing penetration in treatment-naive patient segment



Q1 update

- >8,500 patients treated worldwide; retention rate in first 12 months of ~90% globally
- US: Growth driven by switch and naive patient starts, including patients <2 months old
- Ex-US: Continued strong growth and share gains in all major markets
- Ph II/III (SUNFISH) 4year data presented at MDA 2023

Outlook 2023

- Continued growth and market share gains
- EU: Label extension (<2 months old) based on Ph II (RAINBOWFISH) expected

CER=Constant Exchange Rates

Evrysdi: 4 year data reinforce strong efficacy and safety profile

Ph II/III (SUNFISH) results in SMA



Ph II/III (SUNFISH) safety in SMA



- Increase in motor function scores achieved in first year sustained after 4 years, compared to natural history data
- Overall AE rate decreased over 48 months, with AEs and SAEs reflective of underlying disease; treatment adherence at 99% and no treatment-related AEs leading to withdrawal or treatment discontinuation
- Diverse study population aged 2 to 25 years incl. more advanced disease (e.g. >65% of patients with scoliosis) reflecting a real-world population underserved in clinical trials

Source: Natural history cohort, Roche data on file; courtesy of Association Institut de Myology; first presented at MDA 2021. MFM32=32-item motor function measure; SMA=spinal muscular atrophy; PY=patient years; AE=adverse event; SAE=serious adverse event; *+/- 95% Confidence interval †Baseline is the last measurement prior to the first dose of risdiplam or placebo. ‡Data cut-off: 6 Sep 2022. §Data cut-off: 6 Sep 2019.; Number of patients with valid results = number of patients with an available total score (result) at respective time points

Ophthalmology: Excellent Vabysmo launch continues

*Double-digit US market share in nAMD and mid single-digit in DME**



Q1 update

Vabysmo

- US: Strong uptake with switches primarily from aflibercept; use in naive patients further accelerating
- >860k vials shipped globally in first 14 months of launch
- Positive Ph III (BALATON/COMINO) results for Vabysmo in RVO presented at Angiogenesis 2023
- Ph III post-hoc analyses in nAMD & DME indicating greater retinal drying for Vabysmo vs aflibercept presented at ARVO 2023 (23-27 April)

Susvimo

- Positive Ph III (PAGODA/PAVILLION) results for Susvimo in DME/DR presented at Angiogenesis 2023

Outlook 2023

- Vabysmo: Continued growth and market share gains in nAMD & DME

nAMD=neovascular age-related macular degeneration; DME=diabetic macular edema; RVO=retinal vein occlusion; DR=diabetic retinopathy; *Based on February 2023 patient claims data; Eylea (aflibercept) is a registered trademark/product of Regeneron

Vabysmo: Positive results in RVO presented at Angiogenesis 2023

Improvement in macular leakage compared to aflibercept

Roche

VABYSMO

MIAMI Angiogenesis 2023

Ph III (BALATON/COMINO) results in RVO



- Vabysmo achieved robust BCVA gains and reductions in CST across both studies
- At week 24, more patients on Vabysmo achieved absence of macular leakage vs aflibercept
- Results to be filed globally with regulatory authorities

[1]BCVA was measured using the ETDRS visual acuity chart at a starting distance of 4 m; [2]CST is measured as ILM-BM, as graded by central reading center; [3]Macular leakage was a pre-specified exploratory endpoint in BALATON/COMINO. Macular leakage area within ETDRS grid was assessed by the reading center based on FA (fluorescein angiography) images obtained at baseline and predefined follow-up intervals, Absence is defined as area of leakage within the macula of 0 mm2 per FA; (B)RVO=(branch) retinal vein occlusion; CRVO=central retinal vein occlusion; HRVO=hemiretinal vein occlusion; BCVA=best-corrected visual acuity; ETDRS=early treatment diabetic retinopathy study; CST=central subfield thickness; BM=Bruch's membrane; Eylea (aflibercept) is a registered trademark/product of Regeneron

2023: Key late-stage news flow*

	Compound	Indication	Milestone	
Regulatory	**Hemlibra**	Moderate hemophilia A	EU approval	✓
	Polivy + R-CHP	1L DLBCL	US approval	✓
	Vabysmo	RVO	US approval/EU filing	
	Tecentriq	Subcutaneous administration	US approval/EU filing	✓ EU filing
	Columvi (glofitamab)	3L+ DLBCL	US/EU approval	
	Xofluza	Influenza (paediatric 1+ yrs.)	EU approval	✓
Phase III / pivotal readouts	**Tecentriq + Avastin**	Adjuvant HCC	Ph III IMbrave050	✓
	Tecentriq + chemo	Neoadjuvant / adjuvant TNBC	Ph III GeparDouze/NSABP B-59	
	Tecentriq	Adjuvant SCCHN	Ph III IMvoke010	
	Tecentriq + chemo	Adjuvant TNBC	Ph III IMpassion030	✗
	Tiragolumab + Tecentriq	1L PDL1+ NSCLC	Ph III SKYSCRAPER-01	
	Tiragolumab + Tecentriq + chemo	1L esophageal cancer	Ph III SKYSCRAPER-08 (China only)	
	Venclexta + dexamethasone	t(11;14) R/R MM	Ph III CANOVA	
	Venclexta + azacitidine	1L high risk MDS	Ph III VERONA	
	Alecensa	Adjuvant ALK+ NSCLC	Ph III ALINA	
	Phesgo OBI (on body injector)	HER2+ BC	Ph I *(pivotal)*	
	Crovalimab	PNH	Ph III COMMODORE 1/2	✓
	Columvi + GemOx	2L+ DLBCL	Ph III STARGLO	
	Lunsumio + Polivy	2L+ DLBCL	Ph III SUNMO**	
	Delandistrogene moxeparvovec (SRP-9001)	DMD	Ph III EMBARK	
	Ocrevus 6m SC	RMS / PPMS	Ph III OCARINA II	
	TNKase	Stroke patients 4.5-24h	Ph III TIMELESS	
	Susvimo	DME	Ph III PAGODA	✓
	Susvimo	DR	Ph III PAVILION	✓
	Xolair	Food allergy	Ph III OUtMATCH	

* Outcome studies are event-driven: timelines may change; ** Results are event-driven; read-outs expected in 2023/24

Diagnostics Division

Matt Sause
CEO Roche Diagnostics

Q1 2023: Diagnostics Division sales

Good base business growth, partially offsetting COVID-19 sales decrease

	2023	2022	Change in %	
	CHFm	CHFm	CHF	CER
Diagnostics Division	**3,623**	**5,286**	**-31**	**-28**
Core Lab	1,928	1,896	2	7
Molecular Lab	593	1,189	-50	-48
Point of Care	397	1,466	-73	-72
Diabetes Care	376	417	-10	-5
Pathology Lab	329	318	3	7

CER=Constant Exchange Rates

Diagnostics Division sales growth by quarter

Good base business growth in Q1 2023



Growth rates and absolute values at CER (Constant exchange Rates); [1] Quarterly sales growth excluding COVID-19 sales

Q1 2023: Diagnostics Division highlights

Good base business growth, partially offsetting COVID-19 sales decrease



CER=Constant Exchange Rates; POC=point of care; EMEA=Europe, Middle East and Africa;

Q1 2023: Diagnostics Division regional sales

Strong base business growth across all regions impacted by lower COVID-19 sales



Growth rates at CER (Constant exchange Rates); EMEA=Europe, Middle East and Africa

Largest installed base worldwide with significant growth potential



2022 Growth

Growth rates – from 31.12.2021 to 31.12.2022
(Total installed modules as of 31.12.2022)

[1] cobas 6000 has been discontinued in CE mark countries and replaced with cobas pro / pure systems

Core Lab menu expansion driving future growth

>240 assays running on >100k installed cobas® serum work area instruments

Launches in 2021, 2022 and upcoming[4]

Immuno chemistry assays

- EBV EBNA IgG (CE)
- EBV VCA IgG (CE)
- EBV IgM (CE)
- Anti-p53 (CE)
- GAAD (CE)
- NT-proBNP claim extension[1] (CE)
- TnT-hs claim extension[1] (CE)
- PCT CE claim extension[1] (CE)
- Vit D total III[2] (CE & US)
- Anti-HBe (US)
- Sirolimus (CN)
- HBsAg Confirmatory[2] (CE)
- Alzh CSF biomarkers (CE)
- IGRA SARS-CoV-2 (CE)
- HCV Duo (CE)
- Anti-HAV II[2] (CN)
- HBsAg Confirmatory[2] (US)
- AFP-L3 (CE)
- FT4 IV[2] (CE)
- Alzh CSF biomarker (US)
- Anti-HEV IgG and Anti-HEV IgM (CE)
- GAAD[2] (CE)
- Maxi-Multipack RBSS (CE)
- HBeAg Quant (CE)
- Interferon Gamma (CE)
- NT-proBNP diagnosis ICON-RL[2] (US)
- NT-proBNP STRONG-HF (GL)
- Cortisol III urine application[2] (CE)
- tTAU CSF (Ver 2)
- Elecsys progesterone Diluent[2]
- FT4 IV[2] (US)
- IL6 - Claim extension neonatal (CE)
- Vitamin D total III[2] (CN)

Clinical chemistry assays

- Fentanyl[3] (CE, US)
- sTfR Gen 2[2] (CE)
- CRP4 (CN)
- Benz 2[2] (US)
- NH3L2 (CN)
- ASTP2/ALTP2 cobas 303[2] (CE/US)
- ASTP2/ALTP2 cobas c 503[2] (CE/US)
- BENZ2[2] (US)
- sTfR Gen.2[2] (CN)[2]
- free PHNY2

Launched in 2021 | Launched in 2022 | Upcoming Launches

[1] Claim extension, [2] Product update; [3] Partner Channel. EBV: Epstein-Barr-Virus; [4] non exhaustive, EBNA: Epstein-Barr virus nuclear antigen, VCA: viral capsid antigens, IgM: Immunoglobulin M, anti-p53: autoantibodies, GAAD: in-vitro diagnostic multivariate index assay, NT-proBNP: N-terminal prohormone of brain natriuretic peptide, TnT–hs: Troponin T-high sensitive, PCT: Procalcitonine, Vit D: vitamin D, Anti-HBe: hepatitis B e antigen (HBeAg), HBsAg: hepatitis B surface antigen, Alzh CSF: Alzheimer's disease Cerebrospinal Fluid, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, HCV: Hepatitis C virus, Anti-HAV: antibodies against Hepatitis A virus, AFP-L3: Lectin-reactive fraction of alpha-fetoprotein, FT4: Free Thyroxine (T4), HEV: Hepatitis E virus, RBSS: Roche Blood Safety Solution, NT-proBNP STRONG-HF Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testing of Heart Failure Therapies, tTau CSF: total tau protein concentration in human cerebrospinal fluid (CSF), IL6: Interleukin-6, sTfR Gen 2: Soluble Transferrin Receptor Generation 2, CRP4: C-reactive protein generation 4, BENZ: Benzodiazepines, NH3L2: Ammonia Gen.2, ASTP2: aspartate aminotransferase with pyridoxal phosphate activation Gen.2, ALTP2: alanine aminotransferase with pyridoxal phosphate Gen.2, free PHNY2: free phenytoin.

navify Marketplace and Algorithm Suite

Roll-out of two new digital solutions which will drive operational and clinical excellence

Customer base » **Customer access to Portal/Marketplace[2]** » **Access to applications[3]**



Roche instruments

3rd party devices

IT systems[1]

cobas infinity Central Lab

navify Portal/ Marketplace

NEW

navify Algorithm Suite

navify Inventory

navify Monitoring

navify Control

navify Analytics

navify Sample Tracking

Laboratories

Roche and 3rd party customers

navify Portal/ NEW Marketplace

digital store to directly connect to our and 3rd party's portfolio of innovative and certified applications

NEW **navify Algorithm Suite**

partnership with laboratories to provide trusted clinical diagnosis & decision support for clinicians

[1] Middle ware, [2] navify Portal for customers; navify Marketplace for non-customers, [3] Embedded in Network or with user-interface

VENTANA FOLR1 (FOLR1-2.1) RxDx assay

First FDA approved FOLR1 companion diagnostic test for ovarian cancer



- 322k estimated cases of ovarian cancer worldwide (2021)[1]
- First FDA-approved IHC companion diagnostic test for determining FRα protein expression in epithelial ovarian cancer (EOC)
- Enables pathologists to identify patients who may be eligible for a new therapy, ELAHERE ®[2]
- Runs on automated BenchMark series of instruments

[1] Clarivate Epidemiology Report: Ovarian Cancer, Clarivate Plc. Accessed 04/07/2023 ; [2] Results from the SORAYA clinical study demonstrated ~32 % of eligible patients showed a partial or complete response to ELAHERE therapy; [3] The VENTANA FOLR1 (FOLR-2.1) RxDx Assay was used as part of the SORAYA clinical study to identify patients whose tumors were positive for FRα protein (≥ 75% of viable tumor cells with moderate (2+) and/or strong (3+) membrane staining). In this study, approximately 35% of ovarian cancer patients expressed high levels of FRα (defined as ≥ 75% tumour cells staining with 2+/3+ intensity) and were considered FRα-positive by the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Roche. VENTANA FOLR1 (FOLR-2.1) RxDx Assay. US Package Insert. 2022. Matulonis UA, et al. Abstract LB4. Presented at Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer. March 18-21, 2022.

Diagnostics key launches 2023

	Area	Product	Description	Markets	Status
Instruments Automation	Core Lab	CCM Vertical	Modular transportation system, integrated into the existing cobas connection modules, allowing for overhead sample transportation over different work areas or different floors enabling effective use of lab space	Global	
		cobas pro integrated solutions	Scalable and modular serum work area analyzer for mid to high volume clinical chemistry and immunochemistry testing	China	
		cobas pure integrated solutions	Serum work area analyzer for low to mid volume clinical chemistry and immunochemistry testing on a footprint of two square meters	China	
	Molecular Lab	LightCycler Pro	Flexible real-time PCR instrument with dual IVD and research mode as well as enhanced system features	US & CE	
	Point of Care	cobas pulse	Handheld device combining professional glucose meter and a digital platform to host digital clinical decision support applications (from Roche and third parties)	US	
Tests	Pathology Lab	IDH1 R132H (IDH Glioma)	Neuropathology Immunohistochemistry (IHC) solution supporting the detection of tumor cells with the IDH1 R132H mutation aiding pathologists to render a diagnosis of gliomas	US	✓
	Core Lab	Anti-HEV IgG and Anti-HEV IgM	Anti-HEV IgM: Immunoassay aiding in the diagnosis of acute HEV infection in clinical settings; Anti-HEV IgG: Immunoassay aiding in the detection of a recent or past HEV infection and enabling accurate seroprevalence determinations. The two assays expand the hepatitis panel (HAV, HBV, HCV, HEV) on the same analytical platform	CE	
		HBeAg Quant	Immunoassay aiding in diagnosis, monitoring and predicting treatment response for patients with hepatitis B viral infection	CE	
		IL-6 Neonatal sepsis (claim extension)	Only immunoassay available on the market with dedicated claim and supporting evidence aiding in diagnosis of sepsis in neonates, with potential to reduce newborn mortality	CE	
		RUO Amyloid Plasma Assays (pTau181 & ApoE4)	Two qualitative immunoassays measuring the phosphorylated Tau 181 protein and apolipoprotein E4 in human plasma for research use only	US	
Digital Solutions	Pathology Lab	RUO Digital Pathology Algorithm: PD-L1 SP142	Digital pathology algorithm aiding pathologists in scoring PD-L1 (SP142) breast samples, ensuring a standardized approach and an adjunctive tool to augment diagnostic confidence for research use only	Global	
	Lab Insights	navify Algorithm Suite	Digital solution providing access to an open library of certified IVD-based clinical algorithms	Selected markets[1]	✓
		Menu for navify Algorithm Suite	Certified clinical algorithms for oncology applications such as colon and liver cancers	Selected markets[1]	
		cobas infinity lab 3.05	Next-generation lab middleware enabling ecosystem of cloud-based solutions for quality control and instrument maintenance	Global	
		navify Marketplace	Digital marketplace offering lab customers full range of innovative applications (from Roche and third parties)	Selected markets[1]	✓
		navify Sample Tracking	Open digital solution offering sample tracking beyond the lab setting (from IVD-sample creation to lab reception) to improve testing traceability and quality	Selected markets[1]	

[1] Selected markets: 14 countries with first releases // CE: European conformity; RUO: Research use only; PCR: Polymerase chain reaction; IVD: In vitro diagnostic; IDH: Isocitrate dehydrogenase; HEV: Hepatitis E virus; HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus

Finance

Alan Hippe
Chief Financial Officer

Q1 2023: Highlights

Sales

- Group sales decline of -3% resulting from erosion of COVID-19 related sales
- Solid Pharma and Diagnostics underlying business growth

Currency impact on sales

- Negative currency impact of -4%p primarily by the JPY, EUR and CNY

Growth rates at CER (Constant exchange Rates)

Q1 2023: Regional Pharma and Group sales bridge



Absolute values in CHFm at Constant Exchange Rates (avg full year 2022); [1] avg. full year 2022 to avg Q1 2023 fx impact

Exchange rate impact on sales growth

Negative impact driven by the JPY, EUR and CNY



CER = Constant Exchange Rates (avg full year 2022)

Expected 2023 currency impact





Assuming the 31 March 2023 exchange rates remain stable until end of 2023, 2023 impact[1] is expected to be (%p):

	Q1	HY	Sep YTD	FY
Sales	-4	-5	-5	-4
Core operating profit		-5		-4
Core EPS		-6		-5

[1] On group growth rates

2023 outlook

Group sales growth[1]	Low single digit decline
Core EPS growth[1]	Broadly in line with sales decline
Dividend outlook	Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Upcoming virtual ESG IR event on environmental sustainability

Roche ESG Event on May 23
Environmental Sustainability

15:30 - 17:00 CEST / 14:30 – 16:00 BST
09:30 – 11:00 am EDT / 6:30 – 8:00 am PDT

Why does ESG matter?

Alan Hippe, Chief Financial Officer

Environmental sustainability through operational and product innovation

Carbon emissions and the future of energy

Scott Hemphill, Global Expert in Environmental Sustainability

Sustainable construction

Georg Singewald, Head of Global Manufacturing Science, Technology and Engineering

Product stewardship in Pharma and Diagnostics

Ursina Kohler, Head of Product Stewardship

Water and waste management, and site remediation efforts

Richard Huerzeler, Chief Environment and Remediation Officer

Environmental sustainability in our supply chain

Marielle Beyer, Head of Global Procurement

Doing now what patients need next

Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development (pRED)

Genentech research and early development (gRED)

Spark

Pharma sales appendix

Diagnostics sales appendix

Foreign exchange rates information

Changes to the development pipeline

Q1 2023 update

New to phase I

1AI:
RG6107 crovalimab - lupus nephritis

New to phase II

2 NMEs:
RG6501 OpRegen – geographic atrophy
RG6341 NME – chronic cough

1 AI:
RG6237 latent myostatin – FSHD

New to phase III

1 NME:
RG6149 astegolimab (Anti-ST2) – COPD

1 AI:
RG7159 Gazyva – pediatric nephrotic syndrome

New to registration

Removed from phase I

3 NMEs:
RG6129 HLA-A2-MAGE-A4 x CD3 – solid tumors
RG6290 MAGE-A4 ImmTAC – solid tumors
RG6312 NME – geographic atrophy

Removed from phase II

1 NME:
RG6354 zinpentraxin alfa (PRM-151) - myelofibrosis

Removed from phase III

2 AIs:
RG7446 Tecentriq + cabozantinib – RCC adv
RG7446 Tecentriq + paclitaxel – TNBC adj

Approvals

1 AI (US):
RG7596 Polivy – 1l DLBCL

NME approval in other territory than US and EU:
RG6026 Columvi (glofitamab) – 3L+ DLBCL (First approved in Canada)

Status as of April 26, 2023

Roche Group development pipeline

Phase I (50 NMEs + 12 AIs)

RG6007	HLA-A2-WT1 x CD3	AML
RG6026	Columvi (glofitamab) monotherapy + combos	heme tumors
RG6058	tiragolumab combos	heme & solid tumors
RG6076	englumafusp alfa (CD19-4-1BBL) combos	heme tumors
RG6114	inavolisib (mPI3K alpha inh)	solid tumors
RG6156	EGFRvIII x CD3	glioblastoma
RG6160	cevostamab (FcRH5 x CD3)	r/r multiple myeloma
RG6171	giredestrant (SERD)	solid tumors
RG6180	autogene cevumeran ± T	solid tumors
RG6185	belvarafenib (pan-RAF inh) + Cotellic ± T	solid tumors
RG6189	FAP-CD40 ± T	solid tumors
RG6194	runimotamab (HER2 x CD3)	BC
RG6234	forimtamig (GPRC5D x CD3)	multiple myeloma
RG6264	Phesgo OBI	HER2+ BC
RG6279	eciskafusp alfa (PD1-IL2v) ± T	solid tumors
RG6286	-	colorectal cancer
RG6292	CD25 MAb combos	heme & solid tumors
RG6323	IL15/IL15Ra-Fc ± T	solid tumors
RG6330	divarasib (KRAS G12C)	solid tumors
RG6333	CD19 x CD28 + Columvi (glofitamab)	r/r NHL
RG6344	BRAF inhibitor (3)	solid tumors
RG6392	-	oncology
RG6411	-	solid tumors
RG6433	SHP2i combos	solid tumors
RG6440	Anti-latent TGF-β1 (SOF10)	solid tumors
RG6512	FIXa x FX	hemophilia
RG6524	DLL3 x CD3 x CD137	solid tumors
RG6526[1]	camonsertib	solid tumors
RG6538[2]	P-BCMA-ALLO1	multiple myeloma
RG7446	Morpheus platform	solid tumors
RG7601	Venclexta ± azacitidine	r/r MDS

Status as of April 26, 2023

RG7802	cibisatamab ± T	solid tumors
RG7827	FAP-4-1BBL monotherapy + combos	solid tumors
RG7828	Lunsumio monotheraphy + combos	heme tumors
CHU	glypican-3 x CD3	solid tumors
CHU	codrituzumab	HCC
CHU	CD137 switch antibody	solid tumors
CHU	RAS inhibitor	solid tumors
CHU	SPYK04	solid tumors
SQZ	PBMC vaccine	solid tumors
RG6107	crovalimab	lupus nephritis
RG6287	-	aGVHD
RG6315	-	immunologic disorders
RG6421	TMEM16A potentiator	cystic fibrosis
RG6536[3]	vixarelimab	immunology
RG7828	Lunsumio	SLE
CHU	anti-HLA-DQ2.5 x gluten peptides	celiac disease
CHU	RAY121	immunology
RG6006	zosurabalpin (Abx MCP)	bacterial infections
RG6319	LepB inhibitor	complicated urinary tract infection
RG6035	BS-CD20 MAb	multiple sclerosis
RG6091	rugonersen (UBE3A LNA)	Angelman syndrome
RG6163	-	psychiatric disorders
RG6182	MAGLi	multiple sclerosis
RG6289	-	Alzheimer´s
RG6418*	selnoflast	inflammation
RG7637	-	psychiatric disorders
RG6120	zifibancimig (VEGF-Ang2 DutaFab)	nAMD
RG6209	-	retinal disease
RG6351	-	retinal disease
RG7921	-	RVO
CHU	anti-IL-8 recycling antibody	endometriosis

RG-No - Roche/Genentech; CHU - Chugai managed; SQZ - SQZ Biotechnology managed; [1]Repare Therapeutics managed; [2]Poseida Therapeutics managed; [3]Kiniksa Pharmaceuticals managed; [4]IONIS managed; T=Tecentriq; BS=Brain Shuttle; OBI=On-Body Delivery System; *also developed in Immunology; **combination platform

Phase II (23 NMEs + 9 AIs)

RG6026	Columvi (glofitamab) + chemo	1L ctDNA high risk DLBCL
RG6058	tiragolumab + T	NSCLC
	tiragolumab + T + chemo	NSCLC neoadj-adj
	tiragolumab + T	cervical cancer
	tiragolumab + T	1L PD-L1+ mSCCHN
RG6107	crovalimab	sickle cell disease
RG6139	tobemstomig (PD1 x LAG3)	solid tumors
RG6180	autogene cevumeran + pembrolizumab	1L melanoma
RG6357	dirloctogene samoparvovec (SPK-8011)	hemophilia A
RG6358	SPK-8016	hemophilia A with inhibitors to factor VIII
RG6299[4]	ASO factor B	IgA nephropathy
RG6341	-	chronic cough
RG7854/ RG6346/ RG6084**	ruzotolimod (TLR7 ago[3])/ xalnesiran (siRNA)/ PDL1 LNA	HBV
RG6359	SPK-3006	Pompe disease
RG1662	basmisanil	Dup15q syndrome
RG6042	tominersen	Huntington's
RG6100	semorinemab	Alzheimer's
RG6102	trontinemab	Alzheimer's
RG6237	latent myostatin + Evrysdi	SMA
	latent myostatin	FSHD
RG6416	bepranemab	Alzheimer's
RG7314	balovaptan	post-traumatic stress disorder
RG7412	crenezumab	familial Alzheimer's healthy pts
RG7816	alogabat (GABA Aa5 PAM)	ASD
RG7906	ralmitaront	schizophrenia
RG7935	prasinezumab	Parkinson's
RG6179	anti-IL-6	DME
RG6299[4]	ASO factor B	geographic atrophy
RG6501	OpRegen	geographic atrophy
RG7774	vicasinabin (CB2 receptor agonist)	DR

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Roche Group development pipeline

Phase III (9 NMEs + 40 AIs)

RG3502	Kadcyla + T	HER-2+ eBC high-risk
RG6026	Columvi (glofitamab) + chemo	2L+ DLBCL
RG6058	tiragolumab + T	1L PD-L1+ NSCLC
	tiragolumab + T	1L esophageal cancer
	tiragolumab + T	locally advanced esophageal cancer
	tiragolumab + T	stage III unresectable 1L NSCLC
	tiragolumab + T	1L non-squamous NSCLC
RG6107	crovalimab*	PNH
	crovalimab	aHUS
RG6114	inavolisib (mPI3K alpha inh)	1L HR+ mBC
RG6171	giredestrant (SERD)	1L ER+/HER2- mBC
	giredestrant (SERD)	ER+ BC adj
	giredestrant (SERD) + Phesgo	1L ER+/HER2+ BC
RG6330	divarasib (KRAS G12C)	2L NSCLC
RG7446	Tecentriq + platinum chemo	NSCLC periadj
	Tecentriq	NMIBC, high-risk
	T ± chemo	SCCHN adj
	T + capecitabine or carbo/gem	1L TNBC
	T + Avastin	HCC adj
	Tecentriq	ctDNA+ high-risk MIBC
	T+ lurbinectedin	1L maintenance SCLC
RG7601	Venclexta	r/r MM t(11:14)
	Venclexta + azacitidine	1L MDS
RG7828	Lunsumio + lenalidomide	2L+ FL
	Lunsumio + Polivy	2L+ DLBCL
RG7853	Alecensa	ALK+ NSCLC adj

RG3648	Xolair	food allergy
RG6149	astegolimab (Anti-ST2)	COPD
RG7159	Gazyva	lupus nephritis
	Gazyva	membranous nephropathy
	Gazyva	systemic lupus erythematosus
	Gazyva	pediatric nephrotic syndrome
RG6152	Xofluza	influenza, pediatric (0-1 year)
	Xofluza	influenza direct transmission
RG1594	Ocrevus higher dose	RMS & PPMS
	Ocrevus SC	RMS & PPMS
RG3625	TNKase	stroke
RG6168	Enspryng	myasthenia gravis
	Enspryng	MOG-AD
	Enspryng	autoimmune encephalitis
RG6356	delandistrogene moxeparvovec (SRP-9001)	DMD
RG7845	fenebrutinib	RMS
	fenebrutinib	PPMS
RG6179	anti-IL-6	UME
RG6321	Susvimo (PDS)	DME
	Susvimo (PDS)	DR
	Susvimo (PDS)	wAMD, 36-week
RG7716	Vabysmo (faricimab)	BRVO
	Vabysmo (faricimab)	CRVO

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Registration US & EU (1 NME + 3 AIs)

RG6026	Columvi (glofitamab)	3L+ DLBCL
RG7446	Tecentriq SC	all approved indications
RG6413+ RG6412	Ronapreve[1]	SARS-CoV-2 hospitalized
RG7916	Evrysdi[2]	SMA pediatric <2months

[1]Filed in EU
[2]Approved in US, filed in EU

T=Tecentriq
PDS=Port Delivery System with ranibizumab
*First filed in China in Q3 2022

Status as of April 26, 2023

NME submissions and their additional indications

Projects in phase II and III

- New Molecular Entity (NME)
- Additional Indication (AI)
- Oncology / Hematology
- Immunology
- Infectious Diseases
- Metabolism
- Neuroscience
- Ophthalmology
- Other

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
PDS=Port Delivery System with ranibizumab
*First filed in China
[1]IONIS managed

2023

RG6058	**tiragolumab + T** 1L PD-L1+ NSCLC
RG6058	**tiragolumab + T** 1L esophageal cancer (CN)
RG6107	**crovalimab*** PNH (EU, US)
RG6321	**Susvimo (PDS)** DME (US)
RG6321	**Susvimo (PDS)** DR (US)

2024

RG6026	**Columvi (glofitamab) + chemo** 2L DLBCL
RG6058	**tiragolumab + T** Stage III unresectable 1L NSCLC
RG6114	**inavolisib (mPI3K alpha inh)** 1L HR+ BC
RG6356	**delandistrogene moxeparvovec (SRP-9001)** DMD (EU)

2025

RG6107	**crovalimab** aHUS
RG6321	**Susvimo (PDS)** wAMD, DME, DR (EU)

2026 and beyond

RG6026	**Columvi (glofitamab) + chemo** 1L ctDNA+ high risk DLBCL
RG6058	**tiragolumab + T** 1L PD-L1+ cervical cancer
RG6058	**tiragolumab + T** locally adv esophageal cancer
RG6058	**tiragolumab + T** 1L non-sq NSCLC
RG6058	**tiragolumab + T** 1L PD-L1+ mSCCHN
RG6058	**tiragolumab+T+/- chemo** NSCLC neoadj/adj
RG6107	**crovalimab** sickle cell disease
RG6139	**tobemstomig (PD1xLAG3)** solid tumors
RG6171	**giredestrant (SERD)** 1L ER+/HER2- mBC
RG6171	**giredestrant (SERD)** ER+ BC adj
RG6171	**giredestrant (SERD) + Phesgo** 1L ER+/HER2+ BC
RG6180	**autogene cevumeran** 1L melanoma
RG6330	**divarasib (KRAS G12 C)** 2L NSCLC
RG6149	**astegolimab (anti-ST2)** COPD
RG6299[1]	**ASO factor B** IgA nephropathy
RG6341	**NME** chronic cough
RG7854/ RG6346/ RG6084	**ruzotolimod (TLR7 ago [3])/ xalnesiran (siRNA)/ PDL1 LNA** HBV
RG1662	**basmisanil** Dup15q syndrome
RG6042	**tominersen** Huntington's
RG6100	**semorinemab** Alzheimer's
RG6102	**trontinemab** Alzheimer's
RG6237	**latent myostatin + Evrysdi** SMA
RG6237	**latent myostatin** FSHD
RG6416	**bepranemab** Alzheimer's
RG7314	**balovaptan** post-traumatic stress disorder
RG7816	**alogabat (GABA Aa5 PAM)** ASD
RG7845	**fenebrutinib** RMS
RG7845	**fenebrutinib** PPMS
RG7906	**ralmitaront** schizophrenia
RG7935	**prasinezumab** Parkinson's
RG6179	**anti-IL-6** UME
RG6179	**anti-IL-6** DME
RG6299[1]	**ASO factor B** geographic atrophy
RG6321	**Susvimo (PDS)** wAMD, 36-week refill
RG6501	**OpRegen** geographic atrophy
RG7774	**vicasinabin (CB2 receptor agonist)** DR

Status as of April 26, 2023

AI submissions for existing products

Projects in phase II and III

- New Molecular Entity (NME)
- Additional Indication (AI)
- Oncology / Hematology
- Immunology
- Infectious Diseases
- Metabolism
- Neuroscience
- Ophthalmology
- Other

2023		2024				2025		2026 and beyond	
RG7446	**Tecentriq + Avastin** HCC adj							RG3502	**Kadcyla + Tecentriq** HER-2+ eBC high-risk
RG7601	**Venclexta** r/r MM t(11:14)	RG6264	**Phesgo OBI** HER2+ BC					RG7446	**Tecentriq** High-risk NMIBC
RG7853	**Alecensa** ALK+ NSCLC adj	RG7446	**Tecentriq**[1] NSCLC periadj					RG7446	**Tecentriq+ lurbinectedin** 1l maintenance SCLC
RG1594	**Ocrevus SC** RMS & PPMS	RG7446	**Tecentriq** SCCHN adj	RG7159	**Gazyva** lupus nephritis	RG7828	**Lunsumio (mosun) + lenalidomide** 2L FL	RG7159	**Gazyva** membranous nephropathy
RG3625	**TNKase** stroke	RG7446	**Tecentriq + capecitabine or carbo/gem** TNBC	RG6168	**Enspryng** myasthenia gravis	RG7828	**Lunsumio (mosun) + Polivy** 2L+ DLBCL (US)	RG7159	**Gazyva** systemic lupus erythematosus
RG3648	**Xolair** food allergy	RG7446	**Tecentriq** ctDNA+ high-risk MIBC	RG6152	**Xofluza** direct transmission	RG1594	**Ocrevus higher dose** RMS & PPMS	RG7159	**Gazyva** pediatric nephrotic syndrome
RG7716	**Vabysmo (faricimab)** BRVO/CRVO	RG7601	**Venclexta + azacitidine** 1L MDS	RG6152	**Xofluza** influenza, pediatric (0-1 year)	RG6168	**Enspryng** autoimmune encephalitis	RG6168	**Enspryng** MOG-AD

Status as of April 26, 2023

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
OBI=On-Body Delivery System, Mosun=mosunetuzumab
[1]filing timeline based on data from interim analysis

Major pending approvals 2023

Roche

US	
RG7446	**Tecentriq SC** all approved indications Filed Nov 2022
RG6026	**Columvi (glofitamab)** 3L+ DLBCL Filed Dec 2022

EU	
RG7916	**Evrysdi** SMA presymptomatic pediatric <2mo Filed Nov 2021
RG6413+ RG6412	**Ronapreve*** SARS-CoV-2 hospitalized Filed Jan 2022
RG6026	**Columvi (glofitamab)** 3L+ DLBCL Filed April 2022
RG1569	**Actemra** SS-ILD Filed Aug 2022
RG7446	**Tecentriq SC** all approved indications Filed Nov 2022

China	
RG7916	**Evrysdi** SMA presymptomatic pediatric <2mo Filed June 2022
RG6264	**Phesgo** HER-2+ BC Filed July 2022
RG6107	**crovalimab** PNH Filed Aug 2022
RG6026	**Columvi (glofitamab)** 3L+ DLBCL Filed Dec 2022

Japan-Chugai	
RG6264	**Phesgo** HER-2+ BC/CC Filed Sept 2022
RG1569	**Actemra** Cytokine release syndrome (CRS) Filed March 2023

Status as of April 26, 2023

- New Molecular Entity (NME)
- Additional Indication (AI)
- Oncology / Hematology
- Immunology
- Infectious Diseases
- Metabolism
- Neuroscience
- Ophthalmology
- Other

SC=Subcutaneous
*Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals

Major granted approvals 2023

US	
RG7596	**Polivy** 1L DLBCL (US) April 2023

EU	
RG6152	**Xofluza** influenza pediatric Jan 2023
RG6013	**Hemlibra** moderate hemophilia A Jan 2023

China	
RG7596	**Polivy** 1L DLBCL Jan 2023
RG7596	**Polivy** r/r DLBCL Jan 2023
RG6152	**Xofluza** influenza pediatric 5 to <12 years March 2023

Japan-Chugai

Status as of April 26, 2023

- New Molecular Entity (NME)
- Additional Indication (AI)
- Oncology / Hematology
- Immunology
- Infectious Diseases
- Metabolism
- Neuroscience
- Ophthalmology
- Other